Engaging Policymakers in the States
ATAP AN Support Letter – Massachusetts Section 35 of S3141/H5618 (July 29, 2026) ATAP Action Network asks the Massachusetts House to advance Section 35 of S3141/H5618, which would reduce patient cost-sharing at the point of sale by 80 percent of applicable rebates to address market distortions and lower out-of-pocket drug costs.
ATAP AN Support Letter – Louisiana SB 387 (June 2, 2026) ATAP Action Network asks Governor Landry to sign SB 387 into law to increase transparency and accountability for pharmacy benefit managers and ensure patients do not pay inflated costs for their prescriptions.
ATAP AN Support Letter – Virginia SB 669 (February 19, 2026) ATAP Action Network urges the House Committee on Commerce and Labor to strengthen SB 669 so that 100 percent of rebates are passed through directly to patients at the point of sale rather than to health plans, and to add delinking language that limits PBM compensation to flat fees unlinked from list prices or formulary decisions.
ATAP AN Support Letter – Virginia SB 413 (January 26, 2026) ATAP Action Network asks the Senate Commerce and Labor Committee to advance SB 413, which would prohibit PBMs from deriving income based on drug prices, require clearly defined fees, and reduce patient cost-sharing at the point of sale by 80 percent of applicable rebates, limiting compensation to flat fair-market-value amounts.
ATAP AN Support Letter – Louisiana HB 938 (April 27, 2026) ATAP Action Network supports Louisiana HB 938, which would regulate PBMs by prohibiting spread pricing and barring them from earning income based on service fees, in order to increase transparency and reduce inflated patient costs.
ATAP AN Support Letter – South Carolina H 4794 (April 16, 2026) ATAP Action Network urges the Labor, Commerce and Industry Committee to advance H 4794, which would reduce patient cost-sharing at the point of sale by 100 percent of applicable rebates to remove incentives for high-list-price drugs and lower out-of-pocket costs.
ATAP AN Support Letter – Kansas SB 360 (January 28, 2026) ATAP Action Network asks the Senate Committee on Financial Institutions and Insurance to advance SB 360, which would reduce patient cost-sharing at the point of sale by 100 percent of applicable rebates to address market distortions and lower out-of-pocket drug costs.
ATAP AN Support Letter – New Hampshire SB478 (January 21, 2026) ATAP Action Network asks the Senate Health and Human Services Committee to advance SB478, which would prohibit PBMs from deriving income based on drug prices and require fees to be clearly defined, limiting compensation to flat, fair-market-value amounts unlinked from list prices or formulary decisions.
ATAP AN Support Letter – California SB 41 (September 2025) ATAP Action Network, including the California Rheumatology Alliance, asks Governor Newsom to sign SB 41, which would require PBM licensure and annual reporting while prohibiting practices such as spread pricing to increase transparency and accountability and lower patient costs.
ATAP AN Letter PBMs – Louisiana Special Session (July 2025) ATAP Action Network, including the Rheumatology Alliance of Louisiana, asks Governor Landry to call a special session for more impactful PBM reforms after stronger provisions were removed from HB 264, emphasizing the need for greater transparency and accountability so patients do not pay inflated prescription costs.
ATAP AN Support Letter – Massachusetts H1234 and H1082 (June 10, 2025) ATAP Action Network supports H1234 (80 percent rebate pass-through, ban on spread pricing, and reporting requirements) and H1082 (ban on spread pricing, delinking of PBM compensation from drug prices via flat fees, and audit authority), while encouraging an increase in the pass-through percentage to 100 percent.
ATAP AN Support Letter – Nevada SB316 (June 2, 2025) ATAP Action Network supports Nevada SB316 and asks the committee to strengthen it, noting the bill’s efforts to restrict patient cost-sharing based on monies received by PBMs and to prevent PBMs from earning income based on the cost of a prescription drug.
ATAP AN Support Letter – Louisiana HB264 (May 22, 2025) ATAP Action Network urges House leadership and members to advance HB264, which would mandate that 100 percent of PBM rebates be passed through to patients, addressing market distortions and improving affordability at the pharmacy counter.
ATAP AN Support Letter – CO HB1094 (May 2025, Governor) ATAP Action Network asks Governor Polis to sign HB 1094, which would limit PBMs to flat-dollar service fees, prohibit income based on drug cost or list price, and bar formulary designs that favor certain branded products, thereby removing incentives for high-list-price drugs.
ATAP AN Support Letter – Louisiana HB264 (April 29, 2025) ATAP Action Network asks the House Committee on Insurance to advance HB264, which would require PBMs to pass through 100 percent of rebates to patients to eliminate incentives for high-list-price drugs and reduce out-of-pocket costs.
ATAP AN Support Letter – Maine LD 1580 (April 29, 2025) ATAP Action Network supports Maine LD 1580, which would prohibit spread pricing and prevent PBMs from deriving income based on the list price of a medication, requiring instead only flat-dollar fees consistent with fair market value and unassociated with coverage or formulary placement.
ATAP AN Support Letter – Maine LD 1580 (April 16, 2025) ATAP Action Network supports Maine LD 1580, which would prohibit spread pricing and bar PBMs from earning income based on service fees, limiting compensation to flat, fair-market-value amounts unlinked from drug prices or formulary decisions to reduce incentives for high-list-price drugs.
ATAP AN Support Letter – Arkansas HB1354 (April 2025) ATAP Action Network supports Arkansas HB1354 and urges the committee to strengthen it, noting the bill’s requirements that manufacturer-coupon savings be passed through to patients or public plan sponsors and that related fees be negotiated separately and transparently.
ATAP AN Support Letter – CO HB1094 (April 2025, Committee) ATAP Action Network urges the Senate Health and Human Services Committee to advance HB 1094, which would restrict PBMs to flat-dollar fees, prohibit compensation tied to drug cost, and prevent formulary favoritism of branded products to reduce patient out-of-pocket costs.
ATAP AN Support Letter – Oklahoma SB 1025 (March 2025) ATAP Action Network supports Oklahoma SB 1025, which would require PBMs to pass through 85 percent of rebates to patients, aiming to reduce incentives for high-list-price drugs and lower out-of-pocket costs at the pharmacy counter.
ATAP AN Support Letter – Hawaii SB1509 (March 19, 2025) ATAP Action Network urges the House Committee on Consumer Protection and Commerce to advance SB1509, which would mandate 100 percent rebate pass-through to patients and annual compliance reporting to remove PBM incentives favoring high-list-price drugs.
ATAP AN Support Letter – Hawaii SB1509 (March 11, 2025) ATAP Action Network asks the House Committee on Health to advance SB1509, which would require PBMs to pass through 100 percent of rebates to patients and submit annual compliance certifications, aiming to eliminate incentives for high-list-price drugs and lower costs at the pharmacy counter.
ATAP AN Support Letter – Kansas SB 360 (March 11, 2026) ATAP Action Network urges the House Committee on Insurance to advance SB 360, which would reduce patient cost-sharing at the point of sale by an amount equal to 100 percent of rebates received in connection with the drug, removing incentives for high-list-price products.
ATAP Letter Support VA SB 1078 (January 20, 2025) ATAP, including the Virginia Society of Rheumatology, supports SB 1078, which would reduce patient cost-sharing at the point of sale by at least 80 percent of rebates, and encourages the committee to amend the bill to require a full 100 percent pass-through.
Patients Before Profits – 2025 Louisiana Session (January 2025) This one-page flyer from Patient Access for Louisiana and supporting groups including ATAP calls for passage of SB 194 and HB 264 to ban spread pricing, shift PBM compensation away from drug prices toward flat service-based fees, and increase transparency into contracts, fees, and rebates.